2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100388
    SHP099
    		Inhibitor 99.80%
    SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth.
    SHP099
  • HY-B0183
    Ellagic acid
    		Inhibitor 99.23%
    Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
    Ellagic acid
  • HY-136173
    Batoprotafib
    		Inhibitor 99.41%
    Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
    Batoprotafib
  • HY-116009
    RMC-4550
    		Inhibitor 99.56%
    RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC50 of 0.583 nM.
    RMC-4550
  • HY-141523
    Vociprotafib
    		Inhibitor 99.47%
    Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice.
    Vociprotafib
  • HY-161952
    JAB-3312
    		Inhibitor
    JAB-3312 is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. JAB-3312 has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model.
    JAB-3312
  • HY-162476
    SHP2-IN-28
    		Inhibitor
    SHP2-IN-28 (Compound 7188-0011) is an inhibitor of SHP2 (IC50=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity.
    SHP2-IN-28
  • HY-169111
    SHP2-IN-32
    		Inhibitor
    SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity.
    SHP2-IN-32
  • HY-100388A
    SHP099 monohydrochloride
    		Inhibitor 99.92%
    SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM.
    SHP099 monohydrochloride
  • HY-18756
    NSC-87877
    		Inhibitor ≥99.0%
    NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
    NSC-87877
  • HY-144903
    Migoprotafib
    		Inhibitor 98.06%
    Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor.
    Migoprotafib
  • HY-112368
    PHPS1
    		Inhibitor 99.77%
    PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
    PHPS1
  • HY-153740
    PF-07284892
    		Inhibitor 99.37%
    PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC50 value of 21 nM. PF-07284892 decreases the expression of pERK.
    PF-07284892
  • HY-137092
    IACS-13909
    		Inhibitor 99.97%
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers.
    IACS-13909
  • HY-134885
    RMC-0331
    		Inhibitor 98.96%
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.
    RMC-0331
  • HY-145162
    SHP2-D26
    		Inhibitor
    SHP2-D26 is a first, potent and effective SHP2 degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent.
    SHP2-D26
  • HY-114397
    SHP394
    		Inhibitor 99.66%
    SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM.
    SHP394
  • HY-101964
    SPI-112
    		Inhibitor
    SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.
    SPI-112
  • HY-21336
    3-Azetidinemethanol hydrochloride
    		Inhibitor ≥98.0%
    3-Azetidinemethanol hydrochloride, a medical intermediate, can be used in the synthesis of SHP2 inhibitor.
    3-Azetidinemethanol hydrochloride
  • HY-112478
    PTP Inhibitor IV
    		Inhibitor 99.90%
    PTP Inhibitor IV is a protein tyrosine phosphatase (PTP) inhibitor that competitively inhibits DUSP14 phosphatase activity with an 50 of 5.21 μM. PTP Inhibitor IV inhibits SHP-2, PTP1B, PTP-ε, PTP Meg-2, PTP-σ, PTP-β, and PTP-μ with 50s of 1.8 μM, 2.5 μM, 8.4 μM, 13 μM, 20 μM, 6.4 μM, and 6.7 μM, respectively.
    PTP Inhibitor IV
Cat. No. Product Name / Synonyms Application Reactivity